Out of 10 analysts covering Cempra (NASDAQ:CEMP), 10 rate it “Buy”, 0 “Sell”, while 2 “Hold”. This means 83% are positive. Cempra was the topic in 9 analyst reports since July 30, 2015 according to StockzIntelligence Inc. Below is a list of Cempra Inc (NASDAQ:CEMP) latest ratings and price target changes.
11/12/2015 Broker: Janney Capital Rating: Buy New Target: $43.00 Initiate
16/11/2015 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Old Target: $25.00 New Target: $38.00 Upgrade
23/10/2015 Broker: Cowen & Co Rating: Old Target: $53.00 New Target: $39.00 Target Down
23/10/2015 Broker: Stifel Nicolaus Rating: Buy Old Target: $57.0 New Target: $51.0 Maintain
19/10/2015 Broker: Roth Capital Rating: Buy New Target: $40.00 Target Down
19/10/2015 Broker: TH Capital Rating: Buy Old Target: $56 New Target: $40 Maintain
13/10/2015 Broker: Leerink Swann Rating: Mkt Perform Initiate
The stock increased 0.21% or $0.04 during the last trading session, hitting $19.29. About 666,661 shares traded hands. Cempra Inc (NASDAQ:CEMP) has declined 44.04% since August 31, 2015 and is downtrending. It has underperformed by 48.83% the S&P500.
Cempra Inc. is a clinical-stage pharmaceutical firm focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The company has a market cap of $979.57 million. The Company’s lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. It currently has negative earnings. The Company’s second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States.
The institutional sentiment decreased to 1.14 in Q3 2015. Its down 0.71, from 1.85 in 2015Q2. The ratio turned negative, as 31 funds sold all Cempra Inc shares owned while 45 reduced positions. 28 funds bought stakes while 59 increased positions. They now own 38.41 million shares or 40.72% more from 27.30 million shares in 2015Q2.
Aisling Capital Llc holds 10.73% of its portfolio in Cempra Inc for 2.19 million shares. Abingworth Llp owns 383,935 shares or 6.24% of their US portfolio. Moreover, Opaleye Management Inc. has 4.93% invested in the company for 360,000 shares. The Florida-based Harvey Capital Management Inc has invested 2.49% in the stock. Alpinvest Partners B.V., a Netherlands-based fund reported 40,000 shares.
Since May 27, 2015, the stock had 2 insider purchases, and 0 selling transactions for $86,231 net activity. Dougherty Michael R bought 2,000 shares worth $36,896. Kong Garheng bought 2,830 shares worth $49,335. Goldstein Dov A Md sold 50,000 shares worth $1.79M. Fernandes Prabhavathi sold 9,000 shares worth $321,489.
Cempra Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.